Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00030173 · ClinicalTrials.gov registry record · Phase 1
A Trial to Evaluate Epothilone D in Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 45
- Enrollment target
NCT00030173 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 45 participants.
The verdict
NCT00030173, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 45 participants
- Enrollment target
Study Summary
Epothilone D represents one of a class of cytotoxic macrolides capable of causing mitotic arrest by stabilizing tubulin polymerization. Since microtubules are essential for mitosis, motility, secretion and proliferation, the observed antitumor effects of epothilones have been attributed to their ability to initiate cell death by inhibiting such processes. Epothilone D has demonstrated in vitro cytotoxic activity in a panel of human cell lines, equipotent to that of paclitaxel. In vivo, Epothilone D has also shown significant antitumor activity in a range of xenograft models, including paclitaxel-resistant xenografts. Epothilone D is more potent than paclitaxel in cell lines that demonstrate multiple drug resistant activity overexpressing p-glycoprotein.
Interventions
- DRUG Epothilone D (KOS-862)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2001-10 |
| Est. Completion | 2003-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00030173
The ClinicalTrials.gov registry entry for NCT00030173 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Epothilone D (KOS-862) is the first listed.
NCT00030173 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00030173 about?
NCT00030173 is a clinical study titled "A Trial to Evaluate Epothilone D in Patients With Advanced Solid Tumors". Epothilone D represents one of a class of cytotoxic macrolides capable of causing mitotic arrest by stabilizing tubulin polymerization. Since microtubules are essential for mitosis, motility, secretion and proliferation, the observed antitumor effects of epothilones have been attributed to their abi...
What is the current status of trial NCT00030173?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 2001-10. Estimated completion is 2003-06.
What interventions are being tested in trial NCT00030173?
The interventions under investigation include: Epothilone D (KOS-862) (DRUG).
Who is sponsoring clinical trial NCT00030173?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.